Physician profile
Joe Le
NPI 1154345536
$19,729.72
in general payments reported to CMS, 2019-2025
54 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,208 · 2020: $4,254 · 2021: $3,353 · 2022: $2,412 · 2023: $2,174 · 2024: $2,532 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,444 · Education: $45.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,443.72 |
| Education | $45.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,953.39 | 2019-2025 | Vemlidy, Livdelzi |
| Astrazeneca Pharmaceuticals Lp | $1,962.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,814.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,387.75 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $1,331.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,198.45 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $810.39 | 2019-2023 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $652.83 | 2019-2022 | |
| Pfizer INC. | $633.69 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.68 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $497.58 | 2019-2023 | Spravato |
| Amgen INC. | $435.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Kowa Pharmaceuticals America, INC. | $380.75 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Abbvie INC. | $372.94 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $369.33 | 2019-2023 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.